- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
Vol. 9, No. 3
Fall 2019
The Fall 2019 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
Relevant court decisions highlighted in this issue:
- Allergan Sales, LLC v. Sandoz, Inc.
- INO Therapeutics LLC v. Praxair Distribution Inc.
- Nalpropion Pharms., Inc. v. Actavis Labs FL, Inc.
- Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Labs., Inc.
Relevant ANDA Updates highlighted in this issue:
- ANDA Approvals
- ANDA Litigation Settlements
- Generic Launches
- New ANDA Cases
Related Professionals
Christopher A. Pinahs
Partner
“Wherein” clauses in a method of treatment claim are claim limitations that should be given weight, resulting in the affirmance of a preliminary injunction.
But for a clerical error to be addressed on remand, the Federal Circuit affirms findings of ineligible subject matter and non-infringement.
The Federal Circuit affirmed the district court’s finding that one of the patents was adequately described, but reversed the district court’s finding of non-obviousness.
Plaintiff’s disclaimer of claims found invalid by the PTAB mooted any controversy before the appellate court associated with that patent, and a second patent-in-suit was not invalid because the district court did not err in rejecting the defendants’ obviousness challenge.
While the district court’s finding of literal infringement was reversed, the Federal Circuit affirmed the district court’s finding of infringement under the doctrine of equivalent because the narrowing amendment was tangential to the recited salt in the accused product.
Where the defendants sought out a claim construction in the district court, the Federal Circuit affirmed a finding of non-infringement, and where the defendant did not seek a clarifying claim construction, the Federal Circuit affirmed a finding of infringement.
The court denied defendant’s motion to enforce its settlement agreement with plaintiff after the at-risk launch and subsequent settlement of another defendant.
The asserted claims of 1% ivermectin formulation are invalid on the basis of anticipation in light of a prior art reference that teaches application of 1-5% ivermectin formulation for treatment of the same indication.
Because plaintiffs failed to show specifically how defendants committed any act of infringement in New Jersey—particularly by filing an ANDA in West Virginia with the FDA in Maryland—or that any future, intended acts were a part of the infringement analysis, venue was improper in the District of New Jersey.
The court denies defendant’s motion for judgment of non-infringement in response to ANDA holder modification of its ANDA specification after trial.
Relying on plaintiffs’ testing of defendant’s ANDA product, and finding that the prior art taught away from the claimed invention, the court held the asserted claims valid and infringed.
The court granted plaintiffs’ motion to dismiss defendant’s antitrust and patent misuse counterclaims and related affirmative defenses.
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.